Skip to content

KLRS KLRS Debt-to-equity

Debt-to-equity at other companies

Eli Lilly logo
Eli LillyLLY
1.4×-1.1×
Merck & Co. logo
Merck & Co.MRK
1.1×+0.3×
Amgen logo
AmgenAMGN
6.2×-3.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
0.1×0.0×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
0.1×-0.2×

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+102%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Current ratio12.2×-2.1×

Where this comes from

Calculated from KLRS’s reported figures.

Based on the most recent quarter.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's debt-to-equity?
KLRS (KLRS) reported debt-to-equity of 0× in Q1 2026.
What is the long-term trend for KLRS's debt-to-equity?
Over 2 years (2021 to 2025), KLRS's debt-to-equity has grown at a -62.9% compound annual growth rate (CAGR), from 0.1× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.